Â鶹´«Ã½É«ÇéƬ

Ataxia means “without coordination” and acts as an umbrella term to a group of neurological disorders that affect a person’s balance and muscle control. While the cause of ataxia can vary, it is usually a result of injury to the cerebellum, a part of the brain located near the back of the skull that is responsible for movement and balance but can also be caused by injury to other nerves in the spinal cord.

Ataxia can be separated into three major categories:

• Cerebellar: Damage to the cerebellum affecting vision and balance.

• Sensory: Involves the loss of proprioception, the sense of limb position and movement, and is usually caused by loss of signal in the spinal cord.

• Vestibular: Damage to the vestibular canal in the ear which affects balance and can cause vertigo, nausea and vomiting.

Ataxia can be a symptom of a disease or a disease in itself and can be acquired (as a result of trauma or stroke), genetic (autosomal dominant and autosomal recessive) or sporadic (comorbidity with other diseases, including multiple sclerosis). Furthermore, ataxia can be continuous or episodic, demonstrating the wide variance observed in this disease.

Because the causes and genes associated with ataxia can differ greatly, treatments do too. Some address symptoms and others the underlying cause (e.g. antibacterial or antiviral medications if the ataxia is caused by infection).

Frataxin is a protein that in humans is encoded by the FXN gene. In Friedreich's ataxia, its expression is reduced.

For example, episodic ataxia, of which impaired pyruvate metabolism has been associated, can be treated with acetazolamide (Diamox), a diuretic that can inhibit carbonic anhydrase and subsequently reduce lactate and pyruvate levels in the brain. Additionally, in February, the Food and Drug Administration approved omaveloxolone (Skyclarys) for the first-ever treatment of Friedreich’s ataxia. It acts to rescue Nrf2 from degradation, subsequently preventing oxidative stress, and inhibit the proinflammatory NF-kB pathway.

Cryo-EM picture of a beta-III-spectrin (orange) and F-actin (green) cluster in complex,

Drug discovery is ongoing for ataxia and ataxia-associated disorders. In 2022, researchers the specific pathophysiology for spinocerebellar ataxia type 5. They published their results in the journal Scientific Reports.

SCA5 is a slow, progressive type of ataxia caused by a missense mutation, L253P, in the β-III-spectrin protein. β-III-spectrin is integral for the development of Purkinje cells, nerve cells that reside in the cerebellum. Under normal conditions, β-III-spectrin binds to α-spectrin and actin filaments to form a spectrin-actin cytoskeleton, lining the cytoplasmic side of the plasma membrane and mediating Purkinje cell resiliency and axon connections.

The L253P mutation is located in the actin binding domain of β-III-spectrin and causes a 1,000-fold increase in actin affinity. This subsequently results in an impairment in Purkinje cell dendrite stability and outgrowth, highlighting the importance of proper binding of β-III-spectrin to actin.

published in March the Journal of Biological Chemistry reported the use of an in vitro, protein–protein interaction assay, fluorescence resonance energy transfer, to screen a compound library of FDA-approved drugs to identify compounds that interfere with the β-III-spectrin and actin interaction as an early drug-development campaign. The researchers who conducted the study identified several hit compounds that show reduced binding of β-III-spectrin to actin, and the results suggest these compounds have the potential to be developed as SCA5 therapeutics.

Because ataxia can be caused by a variety of factors, drug development can be tricky. Raising awareness about ataxia and its pathophysiology in different disease states will help to advance the general public’s understanding and the development of further medical interventions to improve the quality of life in those with ataxia.